Tomohiro Nishina Selected Research

Tomohiro Nishina Research Topics

Disease

51	Colorectal Neoplasms (Colorectal Cancer) 01/2024 - 09/2004
47	Stomach Neoplasms (Stomach Cancer) 05/2024 - 09/2000
45	Neoplasms (Cancer) 10/2023 - 09/2000
14	Adenocarcinoma 10/2022 - 01/2012
12	Neutropenia 12/2022 - 08/2005
10	Neoplasm Metastasis (Metastasis) 01/2023 - 09/2000
7	Disease Progression 01/2021 - 04/2010
6	Esophageal Neoplasms (Esophageal Cancer) 04/2024 - 01/2009
4	Hyponatremia 10/2022 - 04/2010
4	Febrile Neutropenia 02/2021 - 07/2016
4	Anemia 01/2019 - 04/2010
4	Diarrhea 07/2016 - 11/2014
3	Exanthema (Rash) 12/2023 - 02/2020
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023 - 10/2011
3	Hepatocellular Carcinoma (Hepatoma) 12/2022 - 04/2014
3	Esophageal Squamous Cell Carcinoma 10/2022 - 01/2009
3	Anorexia 10/2022 - 12/2013
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 09/2004
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2022 - 01/2009
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022 - 01/2021
2	Fatigue 01/2022 - 03/2015
2	Ascites 01/2020 - 09/2012
2	Drug-Related Side Effects and Adverse Reactions 01/2017 - 03/2015
1	Pruritus (Itching) 12/2023
1	Stomatitis 12/2023
1	Taste Disorders (Taste Disorder) 12/2023
1	Acneiform Eruptions 05/2022
1	Nausea 01/2022
1	Irritant Dermatitis 10/2021
1	Dermatitis 10/2021

Drug/Important Bio-Agent (IBA)

22	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2022 - 02/2008
22	Irinotecan (Camptosar)FDA LinkGeneric 01/2022 - 09/2000
18	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 09/2000
16	Bevacizumab (Avastin)FDA Link 11/2023 - 11/2013
16	Cisplatin (Platino)FDA LinkGeneric 08/2022 - 09/2000
16	Leucovorin (Folinic Acid)FDA Link 01/2022 - 12/2007
11	Paclitaxel (Taxol)FDA LinkGeneric 12/2022 - 08/2005
10	Biomarkers (Surrogate Marker)IBA 05/2024 - 04/2014
8	RamucirumabIBA 12/2022 - 07/2016
8	Cetuximab (Erbitux)FDA Link 05/2022 - 11/2008
8	Capecitabine (Xeloda)FDA Link 11/2021 - 08/2005
7	ErbB Receptors (EGF Receptor)IBA 05/2024 - 04/2015
7	pembrolizumabIBA 04/2024 - 01/2020
7	Circulating Tumor DNAIBA 01/2023 - 12/2016
7	S-1 plus cisplatinIBA 05/2021 - 01/2016
6	trifluridine tipiracil drug combinationIBA 11/2023 - 10/2012
6	human ERBB2 proteinIBA 08/2022 - 01/2016
5	Monoclonal AntibodiesIBA 10/2022 - 11/2017
5	Gemcitabine FDA Link 01/2022 - 09/2004
5	Trastuzumab (Herceptin)FDA Link 01/2022 - 07/2012
4	NivolumabIBA 10/2023 - 01/2019
4	Panitumumab (Vectibix)FDA Link 05/2022 - 12/2016
4	TegafurIBA 01/2022 - 09/2010
4	130-nm albumin-bound paclitaxelIBA 01/2022 - 07/2014
4	PlatinumIBA 01/2019 - 12/2013
3	trastuzumab deruxtecanIBA 05/2024 - 01/2021
3	B7-H1 AntigenIBA 09/2023 - 08/2022
3	Albumin-Bound Paclitaxel FDA Link 12/2022 - 07/2014
3	UracilIBA 01/2022 - 02/2015
3	DNA (Deoxyribonucleic Acid)IBA 04/2020 - 01/2019
3	Epidermal Growth Factor (EGF)IBA 02/2020 - 07/2012
2	ZincIBA 12/2023 - 10/2021
2	LigandsIBA 10/2022 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2022 - 02/2020
2	Immune Checkpoint InhibitorsIBA 01/2022 - 03/2021
2	pertuzumabIBA 11/2021 - 02/2020
2	AntibodiesIBA 11/2017 - 12/2012
2	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 08/2016 - 07/2004
2	Formaldehyde (Formol)FDA Link 01/2016 - 01/2016
2	ParaffinIBA 01/2016 - 01/2016
2	Messenger RNA (mRNA)IBA 03/2014 - 01/2009
2	Codon (Codons)IBA 09/2013 - 12/2012
2	AntigensIBA 03/2011 - 06/2008
2	doxifluridineIBA 08/2005 - 07/2004
1	Angiogenesis InhibitorsIBA 01/2024
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2023
1	Mitogen-Activated Protein KinasesIBA 05/2023
1	Phosphotransferases (Kinase)IBA 05/2023
1	Alkaline PhosphataseIBA 12/2022
1	danvatirsenIBA 10/2022
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 10/2022
1	Antisense OligonucleotidesIBA 10/2022
1	durvalumabIBA 10/2022
1	Notch ReceptorsIBA 10/2022
1	NVP-BKM120IBA 10/2022
1	Tetracycline (Achromycin)FDA LinkGeneric 05/2022
1	Minocycline (Cyclops)FDA LinkGeneric 05/2022
1	Sunscreening Agents (Sunscreens)IBA 05/2022
1	folfirinoxIBA 01/2022
1	fms-Like Tyrosine Kinase 3IBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	Topoisomerase I InhibitorsIBA 01/2021
1	napabucasinIBA 11/2020

Therapy/Procedure

56	Drug Therapy (Chemotherapy) 04/2024 - 09/2000
35	Therapeutics 11/2023 - 09/2000
3	Combination Drug Therapy (Combination Chemotherapy) 01/2022 - 12/2013
2	Chemoradiotherapy 11/2020 - 01/2009
2	Radiotherapy 09/2017 - 02/2017
2	Gastrectomy 11/2010 - 05/2006
1	Conformal Radiotherapy 12/2022